Hybridoma Cells
Hybridoma Cells - Related Videos
04:51
A Hybridoma Technology for Producing Monoclonal Antibodies against a Metallopeptidase
0 Views •
2025
This video demonstrates an assay to produce monoclonal antibodies against porcine aminopeptidase N (APN), a membrane-bound metallopeptidase, using a traditional hybridoma technology. Upon immunizing a mouse with APN, the spleen cells are harvested and fused with immortal myeloma cells to produce hybridomas. The hybridomas are then selected and proliferated using the HAT (hypoxanthine-aminopterin-thymidine) medium to produce monoclonal antibodies specific to different APN epitopes.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
01:31
Hybridoma Technology
0 Views •
2023
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy. Hybridoma Selection Commonly used fusion techniques — electroporation, polyethylene glycol...
09:42
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
0 Views •
Cited by 68 •
2017
An optimized protocol is presented for the generation of monoclonal antibodies based on the hybridoma technology. Mice were immunized with an immunoconjugate. Spleen cells were fused by PEG and an electric impulse with immortal myeloma cells. Antibody-producing hybridoma cells were selected by HAT and antigen-specific ELISA screening.
05:00
Localized Surface Plasmon Resonance Imaging to Detect Protein Secretions from a Single Cell
0 Views •
2025
This video demonstrates localized surface plasmon resonance imaging to detect protein secretions from a single cell. Using a microfluidic setup and a peptide-bound plasmonic nanostructure chip, changes in reflected light intensity at the resonance angle reveal interactions with secreted proteins from a single cell.
FAQs
HAT medium creates a selective environment in which unfused parental cells are eliminated, while fused hybrid cells can proliferate and secrete antibody. This selection step is essential because the initial fusion produces a mixed cell population. By enriching for surviving hybrids, researchers obtain cells suitable for establishing a continuous source of a single, highly specific antibody.
The two parental cells contribute complementary properties. The antibody-producing B lymphocyte supplies the capacity to recognize a particular target and secrete its antibody, whereas the myeloma cell contributes immortality. Cell fusion combines these functions in one hybrid, allowing antibody production to continue over time rather than remaining limited to the original immune cell.
Hybridoma-derived antibodies are monoclonal, meaning they originate from a selected hybrid cell and provide a single, highly specific antibody type. This focused specificity supports recognition of particular pathogens, immune markers, or disease-associated molecules. As a result, the antibodies can help researchers detect and characterize defined targets rather than examining broad antibody responses.
The process begins by combining an antibody-producing B lymphocyte with an immortal myeloma cell through cell fusion. The resulting population is placed in HAT medium, which removes unfused parental cells while permitting fused hybrids to proliferate and secrete antibody. The surviving hybridoma population then provides a continuing source of the selected monoclonal antibody.
They are especially useful when experiments require consistent recognition of a pathogen, immune marker, or disease-associated molecule. The resulting monoclonal antibodies support pathogen detection and characterization, as well as investigations of immune-related targets. Their specificity helps connect an observed signal to a defined biological molecule in immunology and infection research.
These antibodies can be incorporated into diagnostic assays to detect defined targets, used for antigen purification, and applied in experimental imaging. They also contribute to targeted therapeutic development by providing antibodies directed toward selected molecules. Together, these applications extend hybridoma technology from basic target characterization to practical detection, isolation, visualization, and treatment-oriented research.